GlassScriptPhysician profile
Richard T Frederick
NPI 1720009160
$142,445.70
in general payments reported to CMS, 2019-2025
13 companies · $46K in 2025
The $46K reported for 2025 was more than what 97% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $32K · 2021: $21K · 2022: $5,211 · 2023: $5,893 · 2024: $21K · 2025: $46K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $45K · Consulting Fee: $13K · Honoraria: $9,540 · Travel and Lodging: $3,789 · Food and Beverage: $2,164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $44,594.75 |
| Consulting Fee | $12,853.00 |
| Honoraria | $9,540.00 |
| Travel and Lodging | $3,789.39 |
| Food and Beverage | $2,164.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $65,843.06 | 2020-2025 | Terlivaz |
| Madrigal Pharmaceuticals | $56,844.99 | 2024-2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $11,737.45 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $3,698.05 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $2,601.54 | 2024-2025 | Iqirvo |
| Gilead Sciences, INC. | $589.74 | 2019-2025 | Livdelzi |
| Cipla USA INC. | $450.00 | 2025 | |
| Tersera Therapeutics LLC | $313.00 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $198.17 | 2019-2025 | Xifaxan |
| Cook Medical LLC | $111.52 | 2025 | Echotip Insight |
| Astrazeneca Uk Limited | $58.18 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Frederick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.